MENU

CK18 as a Biomarker in NASH Clinical Trials

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Scientific Product Manager, DiaPharma Group, Inc.
    Biography
      Dr. Jessica Tuohy is the Scientific Product Manager for Diapharma's biomarker portfolio, which includes assays for studying liver injury in the context of non-alcoholic fatty liver disease, alcoholic hepatitis, metabolic syndrome, and drug-induced liver injury. Jessica received her PhD in Pharmacology from the University of Colorado Health Sciences Center, where she was trained in mass spectrometry of lipids. She contributed to some of the early work in lipidomics in two research positions - first at Cell Therapeutics in Seattle, and subsequently at Vanderbilt University in Nashville, as part of the LIPID-MAPS consortium. Jessica joined Diapharma in 2005. She spent eleven years as the Western Territory Account Manager with a focus on assays for hemostasis, thrombosis and anticoagulation monitoring before she transitioned to her current role as brand ambassador and technical specialist for the company's hepatology and toxicology product lines. When she is not working, Jessica is busy trying to keep up with her three kids - two human and one furry.

    Abstract

    Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in developed countries, and it affects over 25% of the population worldwide. Within the next five years, the more advanced form of this disease, Non-alcoholic steatohepatitis (NASH), is expected to become the leading cause for liver transplants in the US. There are currently no approved pharmacologic therapies for NAFLD or NASH.  Several drug pipelines with diverse mechanisms of action are in clinical development to address this unmet medical need.  While improvement in liver histology confirmed through biopsy is still a required endpoint for regulatory approval, non-invasive biomarkers may be used in early-stage trials to assess treatment effect. Serum Cytokeratin 18 (CK18) levels are reflective of hepatocyte apoptosis and necrosis, which are thought to be important processes involved in the progression of NAFLD. Monitoring serum CK18 levels, therefore, provides mechanistic information on the effect of drug treatment. Furthermore, changes in Serum Cytokeratin 18 Levels have been shown to correlate with changes in liver histology.

    The aims of this talk are to:
    1. Introduce the audience to the growing epidemic of NAFLD
    2. Elucidate challenges in developing therapies for the treatment of NASH
    3. Present data that support the value of CK18 as a biomarker for assessing the efficacy of drugs in NASH clinical trials.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources